Sangamo Therapeutics Inc. buy marge
Start price
28.02.18
/
50%
€21.20
Target price
19.04.18
€31.57
Performance (%)
-17.87%
End price
19.04.18
€17.41
Summary
This prediction ended on 19.04.18 with a price of €17.41. The price of Sangamo Therapeutics Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -17.87%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sangamo Therapeutics Inc. | -9.647% | -9.647% | -78.789% | -88.458% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% | 65.510% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% | 95.368% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% | 42.232% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% | 59.132% |
Comments by marge for this prediction
In the thread Sangamo Bioscienes diskutieren
Sangamo`s Gene editing technology is being highly sought out
Sangamo Therapeutics has a good gene editing technology that Gilead Sciences wanted to get its hands on. One can believe that Sangamo's gene editing technology might be able to improve survival rates in patients with cancer. In any case, Sangamo still has a massive pipeline of three other technologies targeting a variety of diseases.
That means in the small likelihood that this partnership with Gilead Sciences doesn't pan out , it won't be the end of Sangamo.
(Vom Mitglied beendet)
Stopped prediction by marge for Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc.
Start price
Target price
Perf. (%)
€17.41
19.04.18
19.04.18
€26.61
20.12.18
20.12.18
-45.60%
20.12.18
20.12.18
